IBO Advisors Insights

Healthcare Services M&A: What Owners Should Know Before Selling

By Michael Chasen · Updated June 17, 2026

Healthcare services M&A is consolidating faster than owners realize

If you own a home care agency, a dental group, a physical therapy practice, or a behavioral health clinic, you've probably gotten the call. Private equity has been buying up fragmented healthcare services businesses for years, and the pace picked back up in 2026. Middle-market healthcare services M&A entered the year with real momentum, and sponsors have shown increasing conviction deploying capital into high-quality assets, according to Provident Healthcare Partners' Q1 2026 update. In home care specifically, deal activity rose roughly 40.5% year-over-year in 2025, according to Capstone Partners.

Dentistry tells the same story. About 16.1% of U.S. dentists were affiliated with a dental support organization in 2024 - double the 2017 rate, and more than 25% among dentists within a decade of dental school, according to dealseam's DSO tracker. Nearly 200 DSO transactions closed in 2024 alone, according to Benesch's Dental/DSO Industry Newsletter.

The pitch you'll hear is simple: sell now, get a strong multiple, and let a "platform" handle growth. What almost nobody tells you is what you're actually giving up, and that there's a third option that doesn't require it.

Why healthcare roll-ups are different from other PE deals

Private equity doesn't buy your company. They take a mortgage out on it. That's true in any industry. But in healthcare services, the roll-up model comes with two extra layers most owners underestimate: regulatory scrutiny and operational control.

Regulatory scrutiny is intensifying, state by state. At least 25 states have proposed or passed laws increasing oversight of healthcare transactions in recent years, according to Stateline. California's AB 1415 and SB 351, effective January 1, 2026, expanded the state's Office of Health Care Affordability's authority to review deals involving management services organizations and physician or dental platforms, according to National Law Review. In early 2026, Hawaii, Indiana, New York, Pennsylvania, Rhode Island, Vermont, and Virginia all proposed tightening scrutiny of healthcare transactions and strengthening corporate-practice-of-medicine restrictions, according to Nixon Peabody. As oversight has tightened, deal volume in some segments has already started to decline, per Stateline's reporting.

Operational control gets restructured, not eliminated. Most states with a corporate-practice-of-medicine doctrine - including California, Texas, and New York - don't let a non-clinical entity own a physician or dental practice outright. So private equity buyers structure deals through a management services organization, which handles billing, real estate, marketing, and back-office functions while the licensed provider technically stays "in charge" of clinical decisions, according to a Morgan Lewis legal guide. In practice, the MSO holds the economics, the contracts, and often the leverage - even when it can't hold the license. The American Medical Association's Council on Ethical and Judicial Affairs has flagged that private equity firms aren't required to publicly disclose acquisitions, and nondisclosure agreements often obscure who actually controls a practice after the deal closes, according to the AMA's 2024 report.

The two options healthcare owners are usually shown

If you're a home care agency owner, dental group founder, or practice group operator approaching a sale, the conversation almost always narrows to two paths:

Sell to a private equity-backed platform. You get a strong multiple up front, but you typically roll a portion of your proceeds into the platform's equity, accept board-level oversight through the MSO structure, and watch the "platform" acquire other practices in your market - sometimes competitors you used to refer patients to.
Sell to a strategic competitor or larger regional group. Often the fastest close, and usually the option most likely to fold your brand, your staff, and your clinical culture into someone else's system.

Both are real options. Neither is the only one. An Independent Buyout is a third path that exists in the tax code but rarely comes up in these conversations, largely because the advisors running the process are paid by the platform deals they broker - not by transactions where your leadership team is the buyer.

Where an Independent Buyout fits at the right size

An Independent Buyout lets your existing leadership team become the buyer, financed against the business itself using a mechanism that's been in the federal tax code since 1984 (Internal Revenue Code Section 1042) - rather than an outside fund financing the deal with debt placed on your company. The result can look like a private equity outcome on paper - real liquidity, a market-based valuation - without an MSO layer, without a platform board veto, and without your clinics being folded into someone else's roll-up strategy.

For a home care agency, a multi-location dental group, a physical therapy network, or a behavioral health provider generating $3 million or more in EBITDA, that distinction matters more than it does in most industries - because healthcare is one of the few sectors where regulators are actively rewriting the rules on how much control an outside buyer can hold.

	Private Equity Platform Sale (illustrative)	Independent Buyout (illustrative)
Buyer	Outside fund, via an MSO structure	Existing leadership team
Regulatory exposure	Subject to state PE-in-healthcare disclosure and review laws in a growing number of states	Internal transaction; no outside financial sponsor to disclose
Clinical/operational decisions	MSO controls contracts, economics, and often vendor relationships	Leadership retains decision-making authority
Brand and culture	Frequently absorbed into a multi-site platform brand	Preserved under existing leadership
Seller's proceeds	Often a partial rollover into platform equity	Structured around the seller's actual liquidity goals
Tax treatment	Standard taxable sale	Can be structured for tax-advantaged treatment, depending on the seller's specific facts

This table is illustrative, not a guarantee of terms for any specific transaction - actual outcomes vary by deal size, structure, and the seller's individual situation.

What's actually driving the current wave of deals

It's worth understanding why consolidation is happening now, because it changes how you should think about timing. Sponsors are prioritizing scalable, cash-generating platforms with clear reimbursement visibility, according to PwC's 2026 midyear health services deals outlook, and capital is concentrating in sub-sectors like behavioral health, fertility, and home-based care, per CT Acquisitions' 2026 healthcare M&A trends analysis. That means well-run, well-documented practices in these categories are attracting real buyer interest right now - which is exactly the leverage point at which it's worth knowing all of your options, not just the one your broker is compensated to close.

Frequently asked questions

Is private equity actually taking over clinical decisions in these deals? Not directly - corporate-practice-of-medicine laws in most states prevent a non-clinical entity from owning a physician or dental practice outright. But the MSO structure that PE firms use to work around that restriction typically controls the economics, contracts, and back-office decisions that shape how the practice actually operates day to day, according to Morgan Lewis.

Are states actually slowing down healthcare private equity deals? Yes, in a growing number of markets. At least 25 states have proposed or passed laws increasing transaction oversight, and deal activity in some categories has already started to decline as scrutiny increases, according to Stateline.

Does an Independent Buyout work the same way in healthcare as in other industries? The core mechanism is the same - your leadership team becomes the buyer, financed against the business itself. In healthcare specifically, it also sidesteps the MSO layer and the state-level disclosure requirements that increasingly apply to outside-sponsor deals.

What size healthcare business qualifies? IBO Advisors generally works with businesses doing $3 million or more in EBITDA, whether that's a single multi-location practice group or a small regional platform, with every situation evaluated individually.

Is selling through an Independent Buyout really tax-free? It can be structured for tax-advantaged treatment for the seller, depending on the specific facts of the transaction and the seller's individual tax situation. This should be confirmed with a tax advisor before assuming any particular outcome.

Sources

The bottom line

Healthcare services M&A is consolidating fast, and the deal terms private equity offers can look attractive on the surface. But the roll-up model comes bundled with an MSO layer that controls your economics, a wave of new state disclosure and review laws, and a brand and culture that usually gets absorbed into someone else's platform. An Independent Buyout can deliver a comparable liquidity outcome - without handing that control to an outside sponsor in an industry regulators are actively watching more closely every year.

If your company is doing $3M+ in EBITDA and you want to know whether an Independent Buyout is a better fit for your healthcare services business than the next platform offer in your inbox, talk to IBO Advisors about your specific business.

Curious whether an Independent Buyout fits your business?

Learn More